PortfoliosLab logoPortfoliosLab logo
SNY vs. BCE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SNY vs. BCE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sanofi (SNY) and BCE Inc. (BCE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SNY achieves a -1.94% return, which is significantly lower than BCE's 3.77% return. Over the past 10 years, SNY has outperformed BCE with an annualized return of 5.12%, while BCE has yielded a comparatively lower -0.56% annualized return.


SNY

1D
1.44%
1M
3.95%
YTD
-1.94%
6M
-4.06%
1Y
-5.85%
3Y*
0.15%
5Y*
1.27%
10Y*
5.12%

BCE

1D
1.37%
1M
1.12%
YTD
3.77%
6M
6.37%
1Y
18.17%
3Y*
-12.53%
5Y*
-7.49%
10Y*
-0.56%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SNY vs. BCE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SNY
Sanofi
-1.94%4.93%1.09%6.55%0.57%7.00%0.39%20.47%6.06%9.96%
BCE
BCE Inc.
3.77%10.25%-35.53%-4.16%-10.62%28.62%-1.95%23.38%-13.02%16.52%

Correlation

The correlation between SNY and BCE is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.27

Correlation (3Y)
Calculated over the trailing 3-year period

0.32

Correlation (5Y)
Calculated over the trailing 5-year period

0.32

Correlation (10Y)
Calculated over the trailing 10-year period

0.32

Correlation (All Time)
Calculated using the full available price history since Jul 2, 2002

0.32

Fundamentals

Market Cap

SNY:

$108.43B

BCE:

$22.76B

EPS

SNY:

$3.09

BCE:

$6.75

PE Ratio

SNY:

14.58

BCE:

3.62

PS Ratio

SNY:

2.33

BCE:

0.92

PB Ratio

SNY:

1.49

BCE:

1.13

Total Revenue (TTM)

SNY:

$47.35B

BCE:

$24.70B

Gross Profit (TTM)

SNY:

$34.18B

BCE:

$8.56B

EBITDA (TTM)

SNY:

$12.63B

BCE:

$15.98B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SNY vs. BCE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNY
SNY Risk / Return Rank: 3131
Overall Rank
SNY Sharpe Ratio Rank: 3434
Sharpe Ratio Rank
SNY Sortino Ratio Rank: 2828
Sortino Ratio Rank
SNY Omega Ratio Rank: 2929
Omega Ratio Rank
SNY Calmar Ratio Rank: 3333
Calmar Ratio Rank
SNY Martin Ratio Rank: 3232
Martin Ratio Rank

BCE
BCE Risk / Return Rank: 6666
Overall Rank
BCE Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
BCE Sortino Ratio Rank: 6565
Sortino Ratio Rank
BCE Omega Ratio Rank: 6161
Omega Ratio Rank
BCE Calmar Ratio Rank: 6868
Calmar Ratio Rank
BCE Martin Ratio Rank: 6666
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SNY vs. BCE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and BCE Inc. (BCE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SNYBCEDifference
Sharpe ratioReturn per unit of total volatility

-1.14

Sortino ratioReturn per unit of downside risk

-1.53

Omega ratioGain probability vs. loss probability

0.99

1.17

-0.18

Calmar ratioReturn relative to maximum drawdown

-0.27

1.45

-1.72

Martin ratioReturn relative to average drawdown

-0.53

2.97

-3.50

SNY vs. BCE - Sharpe Ratio Comparison

The current SNY Sharpe Ratio is -0.18, which is lower than the BCE Sharpe Ratio of 0.97. The chart below compares the historical Sharpe Ratios of SNY and BCE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SNYBCEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.18

0.97

-1.14

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.05

-0.40

+0.45

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.22

-0.03

+0.25

Sharpe Ratio (All Time)

Calculated using the full available price history

0.21

0.49

-0.28

Drawdowns

SNY vs. BCE - Drawdown Comparison

The maximum SNY drawdown since its inception was -46.46%, smaller than the maximum BCE drawdown of -60.67%. Use the drawdown chart below to compare losses from any high point for SNY and BCE.


Loading charts...

Drawdown Indicators


SNYBCEDifference

Max Drawdown

Largest peak-to-trough decline

-46.46%

-60.67%

+14.21%

Max Drawdown (1Y)

Largest decline over 1 year

-16.70%

-12.27%

-4.43%

Max Drawdown (3Y)

Largest decline over 3 years

-23.37%

-46.88%

+23.51%

Max Drawdown (5Y)

Largest decline over 5 years

-33.52%

-55.42%

+21.90%

Max Drawdown (10Y)

Largest decline over 10 years

-33.52%

-55.42%

+21.90%

Current Drawdown

Current decline from peak

-16.49%

-45.02%

+28.53%

Average Drawdown

Average peak-to-trough decline

-12.19%

-12.83%

+0.64%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.49%

5.99%

+2.50%

Volatility

SNY vs. BCE - Volatility Comparison

Sanofi (SNY) has a higher volatility of 7.29% compared to BCE Inc. (BCE) at 4.97%. This indicates that SNY's price experiences larger fluctuations and is considered to be riskier than BCE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SNYBCEDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.29%

4.97%

+2.32%

Volatility (6M)

Calculated over the trailing 6-month period

15.76%

12.76%

+3.00%

Volatility (1Y)

Calculated over the trailing 1-year period

25.43%

18.46%

+6.97%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

24.77%

18.94%

+5.83%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.46%

19.20%

+4.26%

Dividends

SNY vs. BCE - Dividend Comparison

SNY's dividend yield for the trailing twelve months is around 5.38%, more than BCE's 5.18% yield.


PositionTTM20252024202320222021202020192018201720162015
BCE
BCE Inc.
5.18%6.98%12.47%7.29%6.39%5.37%5.82%5.16%5.84%4.63%5.15%6.00%
SNY
Sanofi
5.38%4.56%4.22%3.83%4.32%3.80%3.61%3.47%4.29%3.82%4.11%3.77%

Financials

SNY vs. BCE - Financials Comparison

This section allows you to compare key financial metrics between Sanofi and BCE Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


4.00B6.00B8.00B10.00B12.00B14.00B20222023202420252026
11.24B
6.18B
(SNY) Total Revenue
(BCE) Total Revenue
Values in USD except per share items

SNY vs. BCE - Profitability Comparison

The chart below illustrates the profitability comparison between Sanofi and BCE Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-20.0%0.0%20.0%40.0%60.0%80.0%20222023202420252026
72.1%
30.0%
Portfolio components
SNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sanofi reported a gross profit of 8.11B and revenue of 11.24B. Therefore, the gross margin over that period was 72.1%.

BCE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BCE Inc. reported a gross profit of 1.86B and revenue of 6.18B. Therefore, the gross margin over that period was 30.0%.

SNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sanofi reported an operating income of 2.27B and revenue of 11.24B, resulting in an operating margin of 20.2%.

BCE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BCE Inc. reported an operating income of 1.28B and revenue of 6.18B, resulting in an operating margin of 20.7%.

SNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sanofi reported a net income of 1.61B and revenue of 11.24B, resulting in a net margin of 14.4%.

BCE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BCE Inc. reported a net income of 654.69M and revenue of 6.18B, resulting in a net margin of 10.6%.


Frequently Asked Questions


SNY and BCE have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SNY has higher volatility (7.29%) compared to BCE (4.97%). In terms of maximum drawdown, SNY dropped -46.46% vs BCE's -60.67%.

BCE currently has the higher Sharpe Ratio (0.97 vs -0.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SNY and BCE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer